Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8223 results

  1. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406

    In development Reference number: GID-TA11341 Expected publication date: TBC

  2. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

  3. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date: TBC

  4. Artificial intelligence software to help detect and characterise colorectal polyps

    In development Reference number: GID-DG10118 Expected publication date: TBC

  5. NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention

    Topic prioritisation

  6. Vacuum Assisted Excision for the removal of breast lesions of uncertain malignant potential

    Topic prioritisation

  7. Transarterial radio embolisation for osteosarcoma liver metastases

    Topic prioritisation

  8. Cryoablation for Desmoid-type Fibromatosis

    Topic prioritisation

  9. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

  10. Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]

    Topic prioritisation

  11. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

  12. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  02 December 2026

  13. Deuruxolitinib for treating severe alopecia areata ID6597

    In development Reference number: GID-TA11804 Expected publication date:  08 October 2026

  14. Kidney Cancer

    In development Reference number: GID-NG10398 Expected publication date:  19 March 2026

  15. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development Reference number: GID-TA11439 Expected publication date: TBC